Corvus Pharmaceuticals (CRVS) announced new preclinical data highlighting the potential of soquelitinib, the Company’s lead ITK inhibitor program, to prevent lung damage, inflammation and ...

(RTTNews) - Corvus Pharmaceuticals Inc. (CRVS) announced new data highlighting the potential of ciforadenant, the Company's adenosine A2A receptor antagonist, to overcome resistance to anti-PD1 ...

Last week, Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS) insiders, who had purchased shares in the previous 12 months were rewarded handsomely. The shares increased by 27% last week, resulting in a ...

Corvus Pharma CRVS is set to give its latest quarterly earnings report on Tuesday, 2024-11-12. Here's what investors need to know before the announcement. Analysts estimate that Corvus Pharma will ...